Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9761MR)

This product GTTS-WQ9761MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9761MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12216MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ3150MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ4621MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986016
GTTS-WQ11195MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ1313MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ4564MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ922MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-221
GTTS-WQ3215MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ARGX-110
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW